Compositions and methods for treating ophthalmic disorders

Patent metadata

Field	Value
Publication number	US-2015368359-A1
Application number	US-201514744532-A
Country	US
Kind code	A1
Filing date	Jun 19, 2015
Priority date	Mar 16, 2006
Publication date	Dec 24, 2015
Grant date	—

Abstract

The present invention relates to compositions and methods for treating ophthalmic disorders of humans or animals. The present compositions and methods are highly suitable for intraocular administration into the interior of an eye and provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision. More specifically, the present invention relates to compositions and methods for treating ophthalmic diseases or disorders with exudative, hemorrhagic and/or inflammatory conditions. Even more specifically, the present invention relates to compositions and methods for treating retinal diseases or disorders, and more specifically ophthalmic diseases or disorders related to impaired retinal vessel permeability and/or integrity.

First claim

1 .- 10 . (canceled)

11 . A method for treating an exudative or inflammatory ophthalmic disorder, the method comprising administering to a subject in need thereof an effective amount of an ophthalmic composition which comprises a plasma kallikrein inhibitor.

12 . The method of claim 11 , wherein the plasma kallikrein inhibitor is a peptide.

13 . The method of claim 12 , wherein the plasma kallikrein inhibitor is an antibody.

14 . The method of claim 13 , wherein the antibody is an immunoglobulin molecule or an immunologically active portion thereof.

15 . The method of claim 14 , wherein the immunologically active portion is a Fab fragment.

16 . The method of claim 11 , wherein the ophthalmic disorder is associated with impaired retinal vessel permeability or integrity.

17 . The method of claim 11 , wherein the ophthalmic disorder is an back-of-eye disease.

18 . The method of claim 17 , wherein the back-of-eye disease is age-related macular degeneration, retinopathy of prematurity, retinal ischemia, choroidal neovascularization, or a retinal disease.

19 . The method of claim 17 , wherein the back-of-eye disease is diabetic retinopathy, diabetic retinal edema, or diabetic macular edema.

20 . The method of claim 11 , wherein the ophthalmic composition is administered to a site of the ophthalmic disorder.

21 . The method of claim 11 , wherein the ophthalmic composition is administered by an ocular route.

22 . The method of claim 21 , wherein the ocular route is intraocular injection.

23 . The method of claim 22 , wherein the intraocular injection is intravitreal injection.

24 . The method of claim 23 , wherein the ophthalmic composition further comprises a biocompatible polymeric component in an amount effective to delay release of the plasma kallikrein inhibitor into the interior of the eye after the composition is administered by the intraocular injection.

Assignees

• Dyax Corp

Inventors

• Belichard Pierre

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P27/00

  Drugs for disorders of the senses · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K2039/505

  comprising antibodies · CPC title